Literature DB >> 28626732

Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications.

Atsushi Hiraoka1, Takashi Kumada2, Masatoshi Kudo3, Masashi Hirooka4, Kunihiko Tsuji5, Ei Itobayashi6, Kazuya Kariyama7, Toru Ishikawa8, Kazuto Tajiri9, Hironori Ochi10, Toshifumi Tada2, Hidenori Toyoda2, Kazuhiro Nouso7, Kouji Joko10, Hideki Kawasaki1, Yoichi Hiasa4, Kojiro Michitaka1.   

Abstract

AIM/
BACKGROUND: The purpose of this study was to evaluate the validity of 3 classifications for assessing liver function, the liver damage and Child-Pugh classifications and the newly proposed albumin-bilirubin (ALBI) grade, in order to examine the feasibility of evaluating hepatic function using ALBI grade with the hepatocellular carcinoma (HCC) treatment algorithm used in Japan.
METHODS: We analyzed the medical records of 3,495 Japanese HCC patients admitted from 2000 to 2015, which were comprised of 1,580 patients hospitalized in the Ehime Prefecture area and used as a training cohort (Ehime group), and 1,915 others who were used for validation (validation group). ALBI score used for grading (≤-2.60 = grade 1, greater than -2.60 to ≤-1.39 = grade 2, greater than -1.39 = grade 3) as well as clinical features and prognosis (Japan Integrated Staging [JIS], modified JIS, ALBI-TNM [ALBI-T] score) were retrospectively investigated.
RESULTS: For prediction of liver damage A, the values for sensitivity and specificity, positive predictive and negative predictive values, and positive and negative likelihood ratios of ALBI-1 and Child-Pugh A were similar among the 2 groups. Akaike information criterion results showed that prognosis based on ALBI grade/ALBI-T score was better than that based on liver damage/modified JIS score and Child-Pugh/JIS score (22,291.8/21,989.4, 22,379.6/22,076.0, 22,392.1/22,075.1, respectively). The cutoff values for ALBI score for indocyanine green retention rate at 15 min (ICG-R15) <10, <20, and <30% were -2.623 (area under the curve [AUC]: 0.798), -2.470 (AUC: 0.791), and -2.222 (AUC: 0.843), respectively. The distribution of ICG-R15 (<10%, 10 to <20%, 20 to <30%, and ≥30%) for ALBI grade 1 was similar to that for liver damage A. There were only small differences with regard to therapeutic selection with the Japanese HCC treatment algorithm between liver damage and ALBI grade.
CONCLUSION: ALBI grade is a useful and easy classification system for assessment of hepatic function for therapeutic decision making.

Entities:  

Keywords:  ALBI grade; Child-Pugh; Hepatocellular carcinoma; Indocyanine green; Liver damage

Year:  2017        PMID: 28626732      PMCID: PMC5473065          DOI: 10.1159/000452846

Source DB:  PubMed          Journal:  Liver Cancer        ISSN: 1664-5553            Impact factor:   11.740


  35 in total

1.  Comparison of the grade evaluated by "Liver damage" of Liver Cancer Study Group of Japan and Child-Pugh classification in patients with hepatocellular carcinoma.

Authors:  Katsuhisa Omagari; Kazuo Ohba; Yoshiko Kadokawa; Hiroaki Hazama; Jun-Ichi Masuda; Hideki Kinoshita; Isao Matsuo; Ken Ohnita; Yohei Mizuta; Kenji Hayashida; Shigeru Kohno
Journal:  Hepatol Res       Date:  2006-02-03       Impact factor: 4.288

2.  Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines).

Authors:  Norihiro Kokudo; Kiyoshi Hasegawa; Masaaki Akahane; Hiroshi Igaki; Namiki Izumi; Takafumi Ichida; Shinji Uemoto; Shuichi Kaneko; Seiji Kawasaki; Yonson Ku; Masatoshi Kudo; Shoji Kubo; Tadatoshi Takayama; Ryosuke Tateishi; Takashi Fukuda; Osamu Matsui; Yutaka Matsuyama; Takamichi Murakami; Shigeki Arii; Masatoshi Okazaki; Masatoshi Makuuchi
Journal:  Hepatol Res       Date:  2015-01       Impact factor: 4.288

Review 3.  Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score).

Authors:  Masatoshi Kudo; Hobyung Chung; Yukio Osaki
Journal:  J Gastroenterol       Date:  2003       Impact factor: 7.527

4.  Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score.

Authors:  Masatoshi Kudo; Hobyung Chung; Seiji Haji; Yukio Osaki; Hiroko Oka; Toshihito Seki; Hiroshi Kasugai; Yo Sasaki; Takashi Matsunaga
Journal:  Hepatology       Date:  2004-12       Impact factor: 17.425

5.  No-mortality liver resection for hepatocellular carcinoma in cirrhotic and noncirrhotic patients: is there a way? A prospective analysis of our approach.

Authors:  G Torzilli; M Makuuchi; K Inoue; T Takayama; Y Sakamoto; Y Sugawara; K Kubota; A Zucchi
Journal:  Arch Surg       Date:  1999-09

6.  Preoperative assessment of liver function: a comparison of 99mTc-Mebrofenin scintigraphy with indocyanine green clearance test.

Authors:  Deha Erdogan; Bob H M Heijnen; Roelof J Bennink; Mariël Kok; Sander Dinant; Irene H Straatsburg; Dirk J Gouma; Thomas M van Gulik
Journal:  Liver Int       Date:  2004-04       Impact factor: 5.828

7.  Report of the 19th follow-up survey of primary liver cancer in Japan.

Authors:  Masatoshi Kudo; Namiki Izumi; Takafumi Ichida; Yonson Ku; Norihiro Kokudo; Michiie Sakamoto; Tadatoshi Takayama; Osamu Nakashima; Osamu Matsui; Yutaka Matsuyama
Journal:  Hepatol Res       Date:  2016-03       Impact factor: 4.288

8.  A case of hereditary elliptocytosis associated with constitutional indocyanine green excretory defect.

Authors:  F Taketazu; I Sanada; N Ngamatsu; R Mukai; Y Suetomo; N Toyoda; M Takada; K Hida; K Kubota; M Maezawa
Journal:  Jpn J Med       Date:  1984-05

9.  Incorporating albumin-bilirubin grade into the cancer of the liver Italian program system for hepatocellular carcinoma.

Authors:  Anthony W H Chan; Charing C N Chong; Frankie K F Mo; John Wong; Winnie Yeo; Philip J Johnson; Shuangni Yu; Paul B S Lai; Anthony T C Chan; Ka-Fai To; Stephen L Chan
Journal:  J Gastroenterol Hepatol       Date:  2017-01       Impact factor: 4.029

10.  Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade.

Authors:  Hidenori Toyoda; Paul B S Lai; James O'Beirne; Charing C Chong; Sarah Berhane; Helen Reeves; Derek Manas; Richard P Fox; Winnie Yeo; Frankie Mo; Anthony W H Chan; Toshifumi Tada; Mercedes Iñarrairaegui; Arndt Vogel; Nora Schweitzer; Stephen L Chan; Bruno Sangro; Takashi Kumada; Philip J Johnson
Journal:  Br J Cancer       Date:  2016-03-29       Impact factor: 7.640

View more
  50 in total

1.  Albumin-Bilirubin Grade and Hepatocellular Carcinoma Treatment Algorithm.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2017-03-09       Impact factor: 11.740

2.  ALBI Score as a Novel Tool in Staging and Treatment Planning for Hepatocellular Carcinoma: Is It Sufficient?

Authors:  Teh-Ia Huo; Po-Hong Liu; Chia-Yang Hsu
Journal:  Liver Cancer       Date:  2017-10-19       Impact factor: 11.740

3.  ALBI Score as a Novel Tool in Staging and Treatment Planning for Hepatocellular Carcinoma: Advantage of ALBI Grade for Universal Assessment of Hepatic Function.

Authors:  Atsushi Hiraoka; Kojiro Michitaka; Takashi Kumada; Masashi Kudo
Journal:  Liver Cancer       Date:  2017-10-19       Impact factor: 11.740

4.  Pre-transplant ALBI Grade 3 Is Associated with Increased Mortality After Liver Transplantation.

Authors:  Nicole Bernardi; Marcio F Chedid; Tomaz J M Grezzana-Filho; Aljamir D Chedid; Marcelo A Pinto; Ian Leipnitz; João E Prediger; Carolina Prediger; Ariane N Backes; Thais O Hammes; Lea T Guerra; Alexandre de Araujo; Mario R Alvares-da-Silva; Cleber R P Kruel
Journal:  Dig Dis Sci       Date:  2019-01-14       Impact factor: 3.199

5.  Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib.

Authors:  Atsushi Hiraoka; Takashi Kumada; Shinya Fukunishi; Masanori Atsukawa; Masashi Hirooka; Kunihiko Tsuji; Toru Ishikawa; Koichi Takaguchi; Kazuya Kariyama; Ei Itobayashi; Kazuto Tajiri; Noritomo Shimada; Hiroshi Shibata; Hironori Ochi; Toshifumi Tada; Hidenori Toyoda; Keisuke Yokohama; Kazuhiro Nouso; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Korenobu Hayama; Taeang Arai; Michitaka Imai; Kouji Joko; Yohei Koizumi; Yoichi Hiasa; Kojiro Michitaka; Masatoshi Kudo
Journal:  Liver Cancer       Date:  2019-10-18       Impact factor: 11.740

6.  Diffusion kurtosis imaging in the assessment of liver function: Its potential as an effective predictor of liver function.

Authors:  Daisuke Yoshimaru; Yasuo Takatsu; Yuichi Suzuki; Toshiaki Miyati; Yuhki Hamada; Ayumu Funaki; Ayumi Tabata; Chifumi Maruyama; Masahiko Shimada; Maki Tobari; Takayoshi Nishino
Journal:  Br J Radiol       Date:  2018-11-01       Impact factor: 3.039

7.  Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis.

Authors:  Atsushi Hiraoka; Takashi Kumada; Kunihiko Tsuji; Koichi Takaguchi; Ei Itobayashi; Kazuya Kariyama; Hironori Ochi; Kazuto Tajiri; Masashi Hirooka; Noritomo Shimada; Toru Ishikawa; Yoshihiko Tachi; Toshifumi Tada; Hidenori Toyoda; Kazuhiro Nouso; Kouji Joko; Yoichi Hiasa; Kojiro Michitaka; Masatoshi Kudo
Journal:  Liver Cancer       Date:  2018-06-11       Impact factor: 11.740

Review 8.  Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients.

Authors:  Atsushi Hiraoka; Takashi Kumada; Kojiro Michitaka; Masatoshi Kudo
Journal:  Liver Cancer       Date:  2018-11-29       Impact factor: 11.740

9.  Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function.

Authors:  Atsushi Hiraoka; Kojiro Michitaka; Takashi Kumada; Namiki Izumi; Masumi Kadoya; Norihiro Kokudo; Shoji Kubo; Yutaka Matsuyama; Osamu Nakashima; Michiie Sakamoto; Tadatoshi Takayama; Takashi Kokudo; Kosuke Kashiwabara; Masatoshi Kudo
Journal:  Liver Cancer       Date:  2017-09-22       Impact factor: 11.740

10.  The Prognosis of Single Large Hepatocellular Carcinoma Was Distinct from Barcelona Clinic Liver Cancer Stage A or B: The Role of Albumin-Bilirubin Grade.

Authors:  Kuan-Chieh Fang; Wei-Yu Kao; Chien-Wei Su; Po-Chun Chen; Pei-Chang Lee; Yi-Hsiang Huang; Teh-Ia Huo; Chun-Chao Chang; Ming-Chih Hou; Han-Chieh Lin; Jaw-Ching Wu
Journal:  Liver Cancer       Date:  2018-03-14       Impact factor: 11.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.